Veteran finance and corporate strategist focused on growth-stage technology and healthcare investments, combining operating experience with board-level governance and capital-raising expertise. Krista D. McBeath brings experience in strategic M&A advisory, portfolio company scaling, and investor relations, with a track record of working across private equity, venture and corporate development teams to drive value creation and exit outcomes.
Veteran finance and corporate strategist focused on growth-stage technology and healthcare investments, combining operating experience with board-level governance and capital-raising expertise. Krista D. McBeath brings experience in strategic M&A advisory, portfolio company scaling, and investor relations, with a track record of working across private equity, venture and corporate development teams to drive value creation and exit outcomes.
Combines an operator-led, growth-stage investment approach emphasizing scalable technology and healthcare businesses. Prioritizes capital-efficient models, repeatable go-to-market strategies, and governance-ready leadership teams; favors active board engagement, staged capital deployment tied to operational milestones, and disciplined exit planning. Underwrites opportunities with an integrated M&A and capital markets lens, blending venture-like upside with private equity value-creation levers—product-market fit, commercial scaling, and strategic partnerships. Time horizon targets growth-to-exit (3–7 years) with emphasis on risk-managed concentration and measurable KPIs to drive dilution-aware returns.
Combines an operator-led, growth-stage investment approach emphasizing scalable technology and healthcare businesses. Prioritizes capital-efficient models, repeatable go-to-market strategies, and governance-ready leadership teams; favors active board engagement, staged capital deployment tied to operational milestones, and disciplined exit planning. Underwrites opportunities with an integrated M&A and capital markets lens, blending venture-like upside with private equity value-creation levers—product-market fit, commercial scaling, and strategic partnerships. Time horizon targets growth-to-exit (3–7 years) with emphasis on risk-managed concentration and measurable KPIs to drive dilution-aware returns.
| Trades 309 | Longs Won 235/309 76% | Profit Factor 42.98 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $689,300.04 |
| Average Win $236,936.59 | Best Trade (Jun 14) $8.06M | Sharpe Ratio 0.64 |
| Average Loss -$17,505.58 | Worst Trade (Mar 31) -$455,082.71 | Z-Score 6.1 (100%) |
| Commissions $0 | Avg. Trade Length 11m 3w 4d | Expectancy $176,002.22 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 16,393 | 14,754 | 13,115 | 11,475 | 9,836 | 8,197 | 6,557 | 4,918 | 3,279 | 1,639 |